Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Pharmacology stubs
SCH 900271
Другие языки:

    SCH 900271

    Подписчиков: 0, рейтинг: 0
    SCH 900271
    SCH 900271.svg
    Names
    Preferred IUPAC name
    5-[3-(1-Methylcyclopropyl)propyl]-2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-trione
    Identifiers
    3D model (JSmol)
    ChEMBL
    ChemSpider
    DrugBank
    PubChem CID
    UNII
    • InChI=1S/C14H16N2O4/c1-14(5-6-14)4-2-3-8-7-9(17)20-12-10(8)11(18)15-13(19)16-12/h7H,2-6H2,1H3,(H2,15,16,18,19)
      Key: ARJKMWXLIHZLQZ-UHFFFAOYSA-N
    • InChI=1/C14H16N2O4/c1-14(5-6-14)4-2-3-8-7-9(17)20-12-10(8)11(18)15-13(19)16-12/h7H,2-6H2,1H3,(H2,15,16,18,19)
      Key: ARJKMWXLIHZLQZ-UHFFFAOYAP
    • O=C1C=C(CCCC2(CC2)C)C(C(NC(N3)=O)=O)=C3O1
    Properties
    C14H16N2O4
    Molar mass 276.292 g·mol−1
    Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

    SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia. It reduced plasma free fatty acids levels, but without significant flushing, a side effect common with niacin that limits its usefulness. SCH 900271 is currently in human trials.



    Новое сообщение